Summary In this study we show an effect of the glutathione-S-transferase MI (GSTM1) null phenotype on the risk for squamous cell carcinoma (SCC) of the bladder among male smokers in Egypt, with an adjusted odds ratio of 4.8 (95% confidence interval:1.06-21.77). However, no overall effect of the GSTM1 null phenotype on the risk for bladder SCC was observed.
Carcinoma of the urinary bladder is the most common malignancy in many tropical and subtropical countries. There is a well-documented association with chronic urinary schistosomal infection, resulting in squamous cell carcinoma of the bladder (SCC), which is a major cause of morbidity and mortality in the endemic areas (IARC, 1994) . Furthermore, foreign compounds from tobacco smoking may be involved in up to 50% of bladder cancers (transitional cell carcinoma, TCC) in western populations (Cole et al., 1971) , through metabolic intermediates, most of them probably oxidised metabolites from N-nitroso-compounds, aromatic amines and polycyclic aromatic hydrocarbons (IARC, 1986; Wynder and Goldsmith, 1977) .
Glutathione-S-transferase Ml (GSTM 1) detoxifies various carcinogenic electrophiles including epoxides. A protective role against neoplasias associated with smoking has, therefore, been attributed to it. GSTM 1 has polymorphic expression and about half the population in various racial groups lack it (Hussey et al., 1986) . Indeed, a greater susceptibility to lung (Seidegard et al., 1990 ) and larynx cancer (Lafuente et al., 1933) has been shown among smokers lacking GSTM1. Susceptibility to bladder cancer has also been studied, although only transitional cell carcinoma has been considered (Zhong et al., 1993; Lafuente et al., 1993; Bell et al., 1993; Daly et al., 1993; Brockmoller et al., 1994; Lin et al., 1994) . Some of these studies found a protective effect of GSTM1 in bladder cancer (Table I) .
We, therefore, designed a study to determine whether GSTM1 deficiency may confer susceptibility to the squamous cell carcinoma of the bladder associated with schistosomiasis. Our hypothesis is based on the antioxidant properties of this isoenzyme, which is able to metabolise the hydroperoxides of DNA that may be produced in chronic inflammation (Ketterer and Meyer, 1989; Lafuente et al., 1995) . Although SCC of the bladder is not known to be related to smoking, we have attempted to assess the influence of the smoking habit on this carcinogenic process, given the role of the GST system in the metabolism of the toxic products of tobacco. Smoking histories were collected by clinicians during the preoperatory visit, calculating 1 pack-year unit as the number of packs of cigarettes smoked per day x number of years of smoking. A total of 60% of smokers in the SCC group and 83% in the control group were heavy smokers (more than 13 pack -years).
The study of the group of women was performed separately and the results are included for descriptive purposes only, since they show a different phenotype distribution from that in men (Seidegard et al., 1990 ); they do not smoke and for social reasons they are rarely visited for the treatment of schistosomiasis.
Blood samples (2 ml) were obtained from all subjects, frozen at -20°C and sent to Spain for analysis.
Leucocytic GSTM1 was measured in whole blood samples with an enzyme-linked immunoassay (ELISA) using affinitypurified rabbit polyclonal antibody to human GSTM1 (Mukit, Biotrin, Dublin, Ireland). Haemolysed blood (50 ul) was mixed with 125 ,l phosphate-buffered saline (PBS) including 1% bovine serum albumin and 25 Ml Triton X-100.
The remaining procedure was as specified in the Mukit technical bulletin, with the modification introduced by Brockm6ller et al. (1993) for the quantitative calibration of all assays: one batch of electrophoretically pure GSTM1 class protein (from Biotrin) was added to one batch of venous blood (in PBS, 1: 1) from a GSTM1-deficient individual.
Standard curves were plotted between 0.010 and 50 jug ml-' in whole blood. Individuals with enzyme levels below 1 jug ml-1 of blood were considered to be deficient in GSTM1. The mean of GSTM1 cross-reacting proteins for negative individuals was 0.117 ,ug ml-' of blood. aCrude odds ratio in SCC group vs control individuals in the respective stratum. bNumber/total number (%).
For statistical analysis, univariate analysis was performed using chi-square with continuity correction. This enabled us to establish categories for the continuous variables as follows: age (>45 years vs <45 years), smoking habit (smokeers vs non-smokers). The expression of the GSTM1 phenotype was considered as the other epidemiological variable. Stepwise logistic regression was also used to assess the independent contribution of variables. P-values below 0.05 were considered to be statistically significant. 
Results
Our data show a bimodal distribution of GSTM1 content, positioning the antimode at 1 Mg ml-1, thus confirming the previously established antimode described by Brockm6ller et al. (1993) . The mean GSTM1 content was 3.3+0.9, 3.1+ 1.3 and 3.8 + 0.3 ,ug ml-' of blood for positive controls, SCC and SC cases respectively. Table II displays the characteristics of the male population and the crude odds ratio for the three variables studied: GSTM1 phenotype, age and smoking habit, showing an association between the SCC risk and age (more than 45 years old). The frequency of GSTM1-negative individuals was higher in the subgroup of SCC male smokers (69% vs 41%). When adjusted odds ratios were calculated, an association among smoking habit, GSTM1 phenotype and SCC risk was evident, indicating that smokers with this metabolic deficiency have a 4.8-fold risk of developing these cancers (1.06-21.77 CI) (Table III) . Stratification by smoking habit shows that this association was mostly attributable to the high smoking exposure (> 13 pack -years) giving 80% of negative phenotypes in the SCC group vs 40% in the control group, and a crude odds ratio of 12.3 (P=0.007). When all male cases, smokers and non-smokers, were considered, frequencies of negative GSTM1 phenotypes were similar in the groups studied; SCC (59%) and C (50.9%) with no overall effect of the GSTM1 null phenotype on the risk for bladder SCC. Stratification based on tumour characteristics showed the null phenotype to be more common among patients with poorly differentiated lesions (WHO tumour grade G-3 65.8%, as compared with G-2 50% and G-1 33.3%) but these differences were not statistically significant.
In the group of male schistosomiasis cystitis patients (SC) frequencies of negative GSTM 1 phenotypes were similar (57.1% vs 50.9%) and also exhibited a high proportion of negative patients among smokers (66.6%). Females, in general, show a lower proportion of null phenotypes than males (42% SCC vs 46% control), but in this case differences with respect to smoking cannot be demonstrated since all the women were non-smokers.
No difference in GSTM1 content in positive individuals was found between any of the subgroups established.
Discussion
In a recent review, Badawi et al. (1992) stress the multifactorial aetiology of bladder SCC, including the promoting effect of chronic infectious disease. Our results suggest that tobacco smoking may also increase the risk of this malignancy in GSTM1-negative schistosomiasis patients. An effect of smoking on the GSTM1 deficiency-associated risk of cancer has been described in relation to other squamous cell carcinomas such as SCC of lung (Hayashi, 1992) and other tobacco-dependent neoplasms such as TCC of the bladder (Lafuente et al., 1993; Bell et al., 1993) (Table  I ). The coincidence of parasitic genotoxins, tobacco toxicants, greater age (as a non-specific factor) and an increase in oxidative capacity caused by schistosomiasis may favour the development of the neoplasm. In this regard, high rates of p53 gene mutations, which are more frequent in GSTM 1-negative individuals (Ryberg et al., 1994) have recently been reported in SCC bladder cancer, which may be related to cigarette smoking and schistosomiasis (Habuchi et 838 al.. 1993) . In such circumstances. the protection of GSTM1 may be essential because they are predominantly distributed in bladder epithelial cells, providing protection against DNA damage induced by reactive oxygen species as well as against carcinogens from tobacco smoke (Singh et al., 1994) . The possible synergism between schistosomiasis, smoking habit and the absence of the GSTM1 enzyme for SCC may be similar to that described for asbestosis, smoking habit and GSTM1 deficiency in lung cancer (Anttila et al., 1995) . This is the first study of an Egyptian population With reference to the GSTM1 phenotype polymorphism. The distribution of the positive phenotype does not differ from that found in other ethnic populations elsewhere (Lin et al.. 1994) . Attention is drawn to a pharmacogenetic study of the pattern of hydroxylation of debrisoquine (P4501ID6) in Egypt published some years ago (Mahgoub et al., 1979) . reporting that the incidence of poor metabolisers in that population was lower (1%) than that found among British subjects (6%). The present study reveals an increased risk in that (Egyptian) population. since a more active oxidation would increase toxicity of nitroso-compounds and other toxicants coming from parasites or tobacco smoke. Combined genetic studies on cytochrome P450 and GSTM1 polymorphisms are now needed.
Tobacco smoking has been rare in most parts of Africa where bladder cancer associated with schistosomiasis infection is common and so it has been little studied. The association between smoking habit, GSTM1 phenotype and the risk of bladder SCC first reported here. calls for further studies on the influence of this habit in the aetiopathogenesis of this malignancy. On the basis of our results. it appears that the antischistosomal drug, Oltipraz. may be doubly beneficial because it is not only anti-parasitic but also an inducer of phase II enzymes such as the glutathione transferases (Kensler et al.. 1992 
